Key Takeaways
- • Private equity firms have captured approximately $7 billion in taxpayer-funded Medicaid payments for autism therapy services over a six-year period (2019–2024), according to analysis of 275 million Medicaid claims by The 74.
- • Applied Behavior Analysis (ABA), a behavior modification system characterized as unproven and potentially harmful by the investigation, has become the dominant therapy model despite concerns about efficacy and crowding out alternative treatments for autistic children.
- • Federal audits begun during the Biden administration documented widespread fraud in autism therapy across both red and blue states, yet the Trump administration's enforcement response focused on immigration and welfare narratives rather than addressing private equity's systemic role in the sector's financialization.
- • Private equity consolidation in the autism therapy space has enabled scale-based profitability models that prioritize billable hours and therapy intensity over treatment outcomes, raising structural questions about financial incentives misaligned with child welfare.
- • The availability of Medicaid data through DOGE's fraud investigation portal enabled public-interest analysis revealing that fraud concerns extend beyond provider-level misconduct to include PE-driven business models extracting disproportionate value from publicly funded disability services.
Summary
The autism therapy sector has emerged as a significant target for private equity investment, with PE-backed providers capturing approximately $7 billion in Medicaid reimbursements between 2019 and 2024. A comprehensive analysis by The 74, based on examination of 275 million Medicaid claims downloaded from the U.S. Department of Government Efficiency's online fraud portal, documents this explosive growth and raises questions about alignment between financial incentives and therapeutic outcomes for children with autism.
The dominant therapy modality funded through this expansion is Applied Behavior Analysis (ABA), a behavior modification system that The 74's investigation characterizes as unproven and potentially harmful. Despite concerns from therapeutic experts about ABA's efficacy and humanistic limitations, the therapy has crowded out alternative treatment approaches as PE consolidation has accelerated across the sector. The financial structure incentivizes high-volume service delivery and intensive therapy hours, creating business models where growth is decoupled from measurable improvements in child outcomes.
Federal audits initiated during the Biden administration had already identified fraud as endemic across the autism therapy industry, spanning both Republican and Democratic states. Rather than directly addressing systemic issues within private equity-backed service provision, the Trump administration's enforcement response—including aggressive federal raids on therapy centers—focused on narratives attributing fraud to immigration and welfare misuse. The administration's framing obscured the broader financialization problem: legitimate PE operators operating within regulatory boundaries while extracting substantial value from Medicaid at the expense of treatment diversity and child-centered care models.
The investigation leverages publicly available data from DOGE's crowdsourced fraud portal to demonstrate how PE capital flows into health care create structural incentives that, while not necessarily constituting fraud in the legal sense, systematically redirect public resources toward high-margin therapies regardless of comparative effectiveness. This represents an emerging pattern in health care consolidation where private equity captures segments of publicly funded systems, optimizing for financial returns rather than clinical outcomes—a dynamic that extends beyond autism services into broader disability and behavioral health sectors.
The dominant therapy modality funded through this expansion is Applied Behavior Analysis (ABA), a behavior modification system that The 74's investigation characterizes as unproven and potentially harmful. Despite concerns from therapeutic experts about ABA's efficacy and humanistic limitations, the therapy has crowded out alternative treatment approaches as PE consolidation has accelerated across the sector. The financial structure incentivizes high-volume service delivery and intensive therapy hours, creating business models where growth is decoupled from measurable improvements in child outcomes.
Federal audits initiated during the Biden administration had already identified fraud as endemic across the autism therapy industry, spanning both Republican and Democratic states. Rather than directly addressing systemic issues within private equity-backed service provision, the Trump administration's enforcement response—including aggressive federal raids on therapy centers—focused on narratives attributing fraud to immigration and welfare misuse. The administration's framing obscured the broader financialization problem: legitimate PE operators operating within regulatory boundaries while extracting substantial value from Medicaid at the expense of treatment diversity and child-centered care models.
The investigation leverages publicly available data from DOGE's crowdsourced fraud portal to demonstrate how PE capital flows into health care create structural incentives that, while not necessarily constituting fraud in the legal sense, systematically redirect public resources toward high-margin therapies regardless of comparative effectiveness. This represents an emerging pattern in health care consolidation where private equity captures segments of publicly funded systems, optimizing for financial returns rather than clinical outcomes—a dynamic that extends beyond autism services into broader disability and behavioral health sectors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.